The FLUENT study will be closing enrollment at the end of the month, on June 30, 2018! Those diagnosed with Multiple Sclerosis (MS) who are interested in trying Gilenya (fingolimod) for the first time may be eligible to participate. The study simply asks for a few questionnaires and a blood draw at baseline and at the standard 1m, 3m, 6m, and 12m follow-up office visits to help learn more about how this medicine affects the immune system.
Neurology Advisor reports patients who have previously tried one or more injectable therapy (iDMTs) may still see improvement with a switch to a Gilenya pill once a day! Read it here.
If you or anyone you know are interested in learning more about this trial, feel free to call our Research Director, Lindsay, at 703-313-9111 ext. 107, or email her at Lindsay@integratedneurologyservices.com.